Pay in 4 interest-free payments of $5.18 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
If persistent, consider reducing dose
162,163,164 Exa-cel (Casgevy) was approved in November 2023 as the first gene-editing therapeutic drug based on the CRISPR/Cas9 system for treating sickle cell disease (SCD) and transfusion-dependent -thalassemia (TDT)
Direct infusion of nutrients to the bloodstream makes them more bioavailable to depleted cells
postprandial vascular-endpoint trials (e.g., FMD, carotid-femoral pulse wave velocity) are still needed (primary biliary cholangitis
start at the lowest spray count once a day with moderate UV exposure Keep timing consistent each day and do not exceed the daily maximum of two (2) sprays and not for more than three (3) days
US$ 21.87
US$ 26.79
US$ 20.07
US$ 22.31
US$ 27.55
US$ 27.13
US$ 27.45
